An experimental pairing of Eli Lilly's amylin drug eloralintide with tirzepatide, the active ingredient in Mounjaro and Zepbound, produced an average 23.3% weight loss over 48 weeks in adults with obesity and type 2 diabetes, according to Phase 2 results released by Lilly Sept. 30 at the EASD meeting in Milan.
Participants on the highest-dose combination lost about 54 pounds, compared with about 34 pounds, or 14.8%, on the top dose of tirzepatide alone. The combination, called EloraTZP, also lowered A1C more.
